Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development

Epilepsia

Volumn 56, Issue 8, 2015, Pages 1198-1206

  Diamond, Matthew L ^a   Ritter, Anne C ^a   Jackson, Edwin K ^a   Conley, Yvette P ^b,c   Kochanek, Patrick M ^a,c   Boison, Detlev ^d   Wagner, Amy K ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d LEGACY RESEARCH   (United States)

Author keywords

Adenosine; Epileptogenesis; Genetics; Posttraumatic epilepsy; Rehabilomics; Traumatic brain injury

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE KINASE; ECTO 5' NUCLEOTIDASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NT5E PROTEIN, HUMAN; SLC29A1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; EPILEPTOGENESIS; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INJURY SEVERITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUBDURAL HEMATOMA; TRAUMATIC EPILEPSY; BRAIN INJURY; COMPLICATION; EPILEPSY, POST-TRAUMATIC; GENETIC PREDISPOSITION; GENETICS; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL;

5'-NUCLEOTIDASE; ADENOSINE KINASE; ADULT; BRAIN INJURIES; EPILEPSY, POST-TRAUMATIC; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GPI-LINKED PROTEINS; HUMANS; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS;

EID: 84938741522     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13044     Document Type: Article

References (46)

1. Rutland-Brown W, Langlois JA, Thomas KE, et al., Incidence of traumatic brain injury in the United States, 2003. J Head Trauma Rehabil 2006; 21: 544-548.
2. Temkin NR,. Risk factors for posttraumatic seizures in adults. Epilepsia 2003; 44 (Suppl. 10): 18-20.
3. Englander J, Bushnik T, Duong TT, et al., Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. Arch Phys Med Rehabil 2003; 84: 365-373.
4. Kolakowsky-Hayner SA, Wright J, Englander J, et al., Impact of late post-traumatic seizures on physical health and functioning for individuals with brain injury within the community. Brain Inj 2013; 27: 578-586.
5. Wagner AK, Miller MA, Scanlon J, et al., Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI. Epilepsy Res 2010; 90: 259-272.
6. Diamond ML, Ritter AC, Failla MD, et al., IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia 2014; 55: 1109-1119.
7. Boison D,. Adenosine dysfunction in epilepsy. Glia 2012; 60: 1234-1243.
8. Pascual O, Casper KB, Kubera C, et al., Astrocytic purinergic signaling coordinates synaptic networks. Science 2005; 310: 113-116.
9. Robel S, Buckingham SC, Boni JL, et al., Reactive astrogliosis causes the development of spontaneous seizures. J Neurosci 2015; 35: 3330-3345.
10. McGraw J, Hiebert GW, Steeves JD,. Modulating astrogliosis after neurotrauma. J Neurosci Res 2001; 63: 109-115.
11. Li T, Ren G, Lusardi T, et al., Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest 2008; 118: 571-582.
12. Fedele DE, Li T, Lan JQ, et al., Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 2006; 200: 184-190.
13. Kochanek PM, Vagni VA, Janesko KL, et al., Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 2006; 26: 565-575.
14. Wagner AK, Zitelli KT,. A Rehabilomics focused perspective on molecular mechanisms underlying neurological injury, complications, and recovery after severe TBI. Pathophysiology 2013; 20: 39-48.
15. Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. VI. Indications for intracranial pressure monitoring. J Neurotrauma 2007; 24 (Suppl. 1): S37-S44.
16. Temkin NR, Dikmen SS, Wilensky AJ, et al., A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990; 323: 497-502.
17. Gennarelli TA, Wodzin E,. AIS 2005: a contemporary injury scale. Injury 2006; 37: 1083-1091.
18. Baker SP, O'Neill B, Haddon W Jr, et al., The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974; 14: 187-196.
19. Fisher RS, Acevedo C, Arzimanoglou A, et al., ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55: 475-482.
20. Miller SA, Dykes DD, Polesky HF,. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
21. Barrett JC, Fry B, Maller J, et al., Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
22. Knapp K, Zebisch M, Pippel J, et al., Crystal structure of the human Ecto-5′-Nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure 2012; 20: 2161-2173.
23. Li J, Ji L,. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005; 95: 221-227.
24. Schumacher MA, Scott DM, Mathews II, et al., Crystal structures of Toxoplasma gondii adenosine kinase reveal a novel catalytic mechanism and prodrug binding. J Mol Biol 2000; 298: 875-893.
25. Bjursell MK, Blom HJ, Cayuela JA, et al., Adenosine kinase deficiency disrupts the methionine cycle and causes hypermethioninemia, encephalopathy, and abnormal liver function. Am J Hum Genet 2011; 89: 507-515.
26. Wiesner JB, Ugarkar BG, Castellino AJ, et al., Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J Pharmacol Exp Ther 1999; 289: 1669-1677.
27. Cunha RA,. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signal 2005; 1: 111-134.
28. Gomes CV, Kaster MP, Tomé AR, et al., Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 2011; 1808: 1380-1399.
29. Boison D,. Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev 2013; 65: 906-943.
30. Ke R-H, Xiong J, Liu Y, et al., Adenosine A2a receptor induced gliosis via Akt/NF-κB pathway in vitro. Neurosci Res 2009; 65: 280-285.
31. Fedele DE, Gouder N, Güttinger M, et al., Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. Brain 2005; 128: 2383-2395.
32. Diógenes MJ, Neves-Tomé R, Fucile S, et al., Homeostatic control of synaptic activity by endogenous adenosine is mediated by adenosine kinase. Cereb Cortex 2014; 24: 67-80.
33. Gouder N, Scheurer L, Fritschy J-M, et al., Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci 2004; 24: 692-701.
34. Li T, Lytle N, Lan J-Q, et al., Local disruption of glial adenosine homeostasis in mice associates with focal electrographic seizures: a first step in epileptogenesis? Glia 2012; 60: 83-95.
35. Aronica E, Zurolo E, Iyer A, et al., Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy. Epilepsia 2011; 52: 1645-1655.
36. Williams-Karnesky RL, Sandau US, Lusardi TA, et al., Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J Clin Invest 2013; 123: 3552-3563.
37. Kobow K, Blümcke I,. The methylation hypothesis: do epigenetic chromatin modifications play a role in epileptogenesis? Epilepsia 2011; 52 (Suppl. 4): 15-19.
38. Lo Nigro C, Monteverde M, Lee S, et al., NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 2012; 107: 75-83.
39. Gao W-M, Chadha MS, Kline AE, et al., Immunohistochemical analysis of histone H3 acetylation and methylation-evidence for altered epigenetic signaling following traumatic brain injury in immature rats. Brain Res 2006; 1070: 31-34.
40. Lovatt D, Xu Q, Liu W, et al., Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc Natl Acad Sci USA 2012; 109: 6265-6270.
41. Chu S, Xiong W, Parkinson FE,. Effect of ecto-5′-nucleotidase (eN) in astrocytes on adenosine and inosine formation. Purinergic Signal 2014; 10: 603-609.
42. Parkinson FE, Xiong W,. Stimulus- and cell-type-specific release of purines in cultured rat forebrain astrocytes and neurons. J Neurochem 2004; 88: 1305-1312.
43. Sträter N,. Ecto-5′-nucleotidase: structure function relationships. Purinergic Signal 2006; 2: 343-350.
44. Kumar RG, Diamond ML, Boles JA, et al., Acute CSF interleukin-6 trajectories after TBI: associations with neuroinflammation, polytrauma, and outcome. Brain Behav Immun 2015; 45: 253-262.
45. Maegele M, Sauerland S, Bouillon B, et al., Differential immunoresponses following experimental traumatic brain injury, bone fracture and "two-hit"-combined neurotrauma. Inflamm Res 2007; 56: 318-323.
46. Vespa PM, Nuwer MR, Nenov V, et al., Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg 1999; 91: 750-760.